the personal genome machine was used to very rapidly sequence that pathogenic e-coli and it would be developed in two days. the utility of this technology is it is very, very fast. >> so is this technology on the market? >> so we're taking orders right now from customers, primarily biomedical researchers. we expect full commercial relief by the third quarter, and we will be delivering by the end of the year. >> is this a venture type type funding? >> no, we are a public company. >> life technologies is the name of the company. what's the scientific american that you have up here? >> we were able to have a productive partnership with scientific american. >> what is your background? >> i'm a chemist, actually a physical chemist, so i work a lot with sequencing. i was involved in the human genome project 10 years ago. my background is sequencing and i've been -- my background is chemistry and i've been in sequencing for about a decade. >> we're here at the consumer electronics show in las vegas. and here is a quality of life technology center. it is a national science foundation enginee

you may recall the e. coli outbreak in europe a few months ago. so the personal genome machine was use today very rapidly sequence that pathogenic e. coli bacterium, obtain the full sequence so that a screen could be rapidly developed. so the utility of this technology is it's very, very fast. >> host: so is this technology on the market? >> guest: so we're taking orders right now. from customers. >> host: such as? >> guest: such as, again, premarely biomedical researchers -- primarily biomedical researchers. we expect to be in full commercial race by the third quarter. >> host: so, dr. scott, how are you funded? is this a venture capitalist type funding? >> guest: oh, no. we are, um, we are listed, we're a public company, so, yeah. so we're -- >> host: life technologies is the name of the company. what's the scientific american that you have up here on your -- >> guest: yeah. so at this booth we were able to have a very, i think, productive partnership with scientific american both in terms of this particular booth, but also this terms of some ot

proton was used very rampantly, pathogenic e. coli bacterium so the screen could be rapidly developed. we do that in a few days of the utility of the technology is very fast. >> host: is this technology on the market? >> guest: we are taking orders right now from customers. >> host: such as? >> guest: primarily biomedical researchers. we expect to be in full commercial by the end of the third quarter. >> host: dr. scott how are you funded? is this a venture capitalist type funding? >> guest: oh no. we are listed, we are a public company so yeah, -- >> host: life technologies is the name of the company. what is the scientific american thing you have up there? >> guest: at this booth we were able to have a very productive partnership with scientific american in terms of this particular booth but also in terms of wider activities here at ces. >> host: what is your background? >> guest: my background is i am a chemist, so i have worked a lot sequence the -- sequencing and an human genome program a few years ago so my background is in